Giant cell tumors in temporomandibular joint region involving lateral skull base: A literature review

1 Dr. Elias Boutros, 2 Dr. Mohamed Sabe-Alarab, 3 Dr. Fawaz Jaber, 4 Dr. Jehad Kharfan

1 Prof, Ph.D. in Oral and Maxillofacial Surgery, Faculty of Dentistry, Al Andalus University for Medical Sciences Qadmous, Tartous, Syria
2 Prof, PhD in Oral and Maxillofacial Surgery, Faculty of Dentistry, Hama University Hama, Hama, Syria
3 PhD student in Oral and Maxillofacial Surgery, Faculty of Dentistry, Hama University Hama, Hama, Syria
4 Master student in Oral and Maxillofacial Surgery, Faculty of Dentistry, Hama University Hama, Hama, Syria

Abstract

Purpose: To review the literature associated with giant cell tumors in temporomandibular joint and lateral skull base region.

Materials and Methods: A review of the literature was performed to record the tumor location, patient’s personal data, and extent of resection, radiotherapy, recurrence, clinical features, and Follow-up.

Results: Nine articles were identified and reviewed in the presented study. The most common clinical symptoms in GCTs in the TMJ-SB region were malocclusion and restriction of mouth opening, other symptoms such as persistent headache and hypoacusis also were not rare because of skeletal invasion of the skull base and ears. Skull base GCTs occur most commonly in young adults with an equal sex distribution. The total removal of giant cell tumors in TMJ without adjuvant radiotherapy is the most effective treatment for localized disease.

Conclusion: GCTs of the skull commonly affect young adults, with an equal sex distribution, and are most often centered in temporal bone. Total removal is associated with the lowest recurrence rate and should be the goal of treatment. If total removal cannot be achieved, the combination of subtotal removal and radiation results in a similar recurrence rate.

Keywords: giant cell tumor, lateral skull base, temporomandibular joint, temporal bone, radiotherapy

1. Introduction

Giant cell tumors (GCTs) are a group of rare benign neoplasms that are most commonly found in the epiphysis of long bones. Around 1–2% of these lesions present in the head and neck, with the skull base being a commonly reported site (temporal, sphenoid and ethmoid bones) and other sites including the mandible, maxilla, nasal cavity, thyroid, larynx, hyoid, tongue and the soft tissues of the neck. In the skull base the temporal bone is a common site of occurrence of GCTs. Although benign, these tumors have a locally destructive character which can be potentially dangerous in the presence of the intricate neurovasculature of the temporal bone and skull base [1].

To date, only a few reports of GCTs arising in the mandible, larynx, sphenoid, and hyoid bone can be found in the literature. Most of them occurred in the temporomandibular joint and skull base (TMJ-SB) region or involved the lateral skull base [2].

The Purpose of this study is review the literature associated with giant cell tumors in temporomandibular joint and lateral skull base region.

2. Materials and methods

Using a PubMed literature search, we identified and reviewed papers using these key words: giant cell tumor, lateral Skull base, temporomandibular joint, temporal bone, and radiotherapy.

Papers were retrieved from 1987 to 2016 and we recorded the tumor location, patient’s personal data, extent of resection, radiotherapy, recurrence, clinical features, and Follow-up (Table 1).

Table 1: Summary of GCT Cases. 1987 – 2016

<table>
<thead>
<tr>
<th>Study reference</th>
<th>Age/sex</th>
<th>Clinical features</th>
<th>Location</th>
<th>Extent of excision</th>
<th>Adjuvant therapy</th>
<th>Recurrence</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Findlay et al., (1987)</td>
<td>23/M</td>
<td>Hearing loss, otalgia, partial FN paralysis, V never hypesthesia</td>
<td>Temporal</td>
<td>Total removal</td>
<td>RT</td>
<td>No</td>
<td>8 months</td>
</tr>
<tr>
<td>Pai et al., (2005)</td>
<td>26/M</td>
<td>Hearing loss, tinnitus, swelling, FN paralysis, CHL</td>
<td>Temporal</td>
<td>total removal</td>
<td>None</td>
<td>No</td>
<td>1 year</td>
</tr>
<tr>
<td>Elder et al., (2007)</td>
<td>2/F</td>
<td>Mass behind ear, aural discomfort mass in the EAC</td>
<td>Temporal</td>
<td>Total removal</td>
<td>None</td>
<td>No</td>
<td>13 months</td>
</tr>
<tr>
<td>Matsushige et al., (2008)</td>
<td>77/F</td>
<td>Headache, vomiting dizziness, temporal hemorrhage</td>
<td>Temporal</td>
<td>Total removal</td>
<td>None</td>
<td>No</td>
<td>1 year</td>
</tr>
<tr>
<td>Isaacsen et al., (2009)</td>
<td>42/M</td>
<td>Recurrence with otalgia and aural fullness, prior surgery with MCF and subtotal clearance, MHL</td>
<td>Temporal</td>
<td>Total removal</td>
<td>None</td>
<td>No</td>
<td>3 years</td>
</tr>
<tr>
<td></td>
<td>47/M</td>
<td>Recurrence with otalgia and aural fullness, prior surgery with MCF and subtotal clearance, MHL</td>
<td>Temporal</td>
<td>Total removal</td>
<td>None</td>
<td>No</td>
<td>10 years</td>
</tr>
</tbody>
</table>
Iizuka et al, (2012) [8]  
32/M  
| Left aural hearing loss, tinnitus, fullness, EAC bulge, CHL. | Temporal | Total removal | None | No | 4 years |

Zhang et al, (2013) [9]  
34/M  
| Preauricular pain, temporomandibular symptoms. | Temporal | subtotal removal | None | Yes | 18 months |

27/F  
| Headache, dizziness, temporal hemorhage | Temporal | subtotal removal | RT | No | 24 months |

52/M  
| Headache, vomiting dizziness, temporal hemorhage | Temporal | subtotal removal | RT | No | 33 months |

44/M  
| Total hearing loss, EAC bulge. | Temporal | Total remova | RT | No | 21 months |

54/F  
| Preauricular pain, temporomandibular symptoms. | Temporal | Total remova | None | No | 7 months |

19/M  
| Preauricular pain, temporomandibular symptoms | Temporal | Total remova | RT | No | 31 months |

33/M  
| Preauricular pain, temporomandibular symptoms | Temporal | Total remova | None | No | 12 months |

35/F  
| Total hearing loss, EAC bulge. | Temporal | Total remova | None | No | 11 months |

Prasad et al, (2014) [10]  
36/M  
| preauricular mass, hearing loss, tinnitus, temporoparietal, pain | Temporal | Total remova | None | No | 120 months |

31/F  
| hearing loss, tinnitus, HTN, stroke with hemiparesis, SLE | Temporal | Total remova | None | No | 96 months |

46/M  
| temporal swelling; hearing loss, tinnitus, temporoparietal pain | Temporal | Total remova | None | No | 48 months |

67/M  
| hearing loss, tinnitus, vertigo, HTN, vocal cord palsy due to previous thyroid surgery | Temporal | subtotal removal | RT | Yes | 24 months |

57/M  
| hearing loss, tinnitus | Temporal | Total remova | None | No | 15 months |

Yi Sben et al, (2016) [12]  
29/M  
| swelling in the left temporomandibular joint | TMG | Total removal | None | No | 5 Years |

42/M  
| left-sided headache and temporal numbness presented to the outpatient clinic for treatment | Temporal | Total remova | None | No | 5 Years |

71/F  
| trismus, malocclusion, hearing loss, and facial paralysis. | Temporal | Total remova | None | No | 12 months |

FN = Facial nerve; VN = trigeminal nerve; RT = radiotherapy; GCT= giant cell tumor; TMJ= temporomandibular joint; (EAC)= external auditory canal. F= Female. M= male. CHL = conductive hearing loss. SLE = systemic lupus erythematosus; HTN = hypertension; MHL = Mixed hearing loss; MCF= Middle cranial fossa

3. Results
Of 9 papers published on this topic between 1987 and 2016, we were able to retrieve and interpret all of them (Table 1). the most common clinical symptoms in GCTs in the TMJ-SB region were malocclusion and restriction of mouth opening because of the temporomandibular joints, zygomatic arches, and mandibles were the anatomic structures affected by these GCTs in the TMJ-SB region. Other symptoms such as persistent headache and hypoacusis also were not rare because of skeletal invasion of the skull base and ears. Skull base GCTs occur most commonly in young adults with an equal sex distribution. The total removal of giant cell tumors in TMJ without adjuvant radiotherapy is the most effective treatment for localized disease and avoids the risks associated with radiation exposure, including radiation damage to normal surrounding tissues. If total removal is not feasible, then subtotal removal with adjuvant radiotherapy provides acceptable tumor control rates.

4. Discussion
To GCTs of bone arise from differentiated mesenchymal cells of the bone marrow. The majority of GCTs are found in the epiphysis of long bones, with <2% involving the skull [10, 11]. When the cranium is involved, GCTs most commonly arise from the floor of the middle fossa, specifically the temporal and sphenoid bones [3, 12]. Males and females are usually affected equally, and although most are considered benign, GCTs of the skull base may cause extensive local destruction, as seen in our patient. Primary tumors arising from the skull base vary widely based on their cell of origin and include osteoma and osteoblastoma, chondroma, chondroblastoma, chondrosarcoma, chordoma, hemangioma, meningioma, and cholesteatoma [3]; however, bone replacement and mastoid tegmen invasion, also seen in our patient, are less common in these other tumors. Patients with temporal GCTs commonly present with conductive hearing loss, aural fullness, pain behind the ears, and facial weakness [8]. In contrast, sphenoid GCTs present with headaches, facial hypoesthesia, vision failure, and ophthalmoparesis [11]. Although GCTs commonly invade the infratemporal fossa, interfering with middle ear structures and resulting in conductive hearing loss [11, 13]. CT and MRI are excellent tools for characterizing and diagnosing GCTs. On CT, GCTs often appear as soft tissue density masses with destructive expansion into the bone, leaving the cortex intact. However, CT alone is insufficient for differentiating GCTs from other similarappearing masses, such as giant cell reparative granulomas and brown tumors. MRI provides better characterization and delineation of the tumor through its superior contrast resolution and different sequences [14]. The skull bones are reported to be more frequently involved than other parts of the face like the mandible or the maxilla. The difference between dealing with GCTs in other parts of the body, especially the long bones, and in the skull base is manifold. Firstly, the surgical anatomy of the skull base is extremely complicated and hence requires great expertise and
skill in the excision of these tumors. Secondly, total tumor removal is imperative in the first sitting because a recurrence in this complex area would be particularly difficult to treat. Thirdly, it is difficult to be radical in tumor removal of the skull base as resection or injury to vital neurovascular structures leaves an unacceptable degree of morbidity. Finally, the GCTs of the skull base are dealt with by the otology/skull base surgeons, ENT/head and neck surgeons or maxillofacial surgeons who bring with them their expertise and familiarity of the use of the microscope and the microdrill that facilitates precise tumor identification and removal [1].

In Yi Sben et al, (2016) study concluded that Craniomaxillofacial surgery for GCTs in the TMJ region invading the skull base is feasible in selected patients. A meticulous plan via a multidisciplinary approach is mandatory for the success of such treatment [2].

In Prasad et al, (2014) study concluded that GCTs are benign and locally aggressive and this makes surgical management difficult in the skull base due to the complex anatomy. A thorough knowledge of the anatomy of the skull base and the various skull base approaches is necessary to treat this subset of tumors [1].

Based on the results of our literature review of skull base GCTs, we found that total removal without adjuvant radiotherapy for the treatment of cranial GCTs is effective for local treatment of disease. Furthermore, it avoids the risks associated with radiation exposure, including radiation damage to normal surrounding tissues, and precludes the risk of sarcomatous degeneration. If total removal is not feasible, then subtotal removal plus radiotherapy appears to result in acceptable tumor control rates. For many years, chemotherapy had no role in the treatment of GCTs; however, denosumab, a receptor activator of nuclear factor kappa-b ligand (RANKL) inhibitor, is increasingly used in the treatment of GCTs with positive results.

5. Conclusions
GCTs of the skull commonly affect young adults, with an equal sex distribution, and are most often centered in temporal bone. Total removal is associated with the lowest recurrence rate and should be the goal of treatment. If total removal cannot be achieved, the combination of subtotal removal and radiation results in a similar recurrence rate.

6. References